HER2 monoclonal antibody trastuzumab has achieved exciting results in the treatment of breast cancer; however, Phase II clinical trials confirmed that trastuzumab is not effective in the treatment of ovarian cancer [8], which may be due to this novel HIF-1/NOX4 pathway. Here, HIF1A is linked to ovarian cancer.